Letter from the Editor

Dear colleagues,

30 years of UEG was celebrated during the UEG Week 2022 in Vienna this year. For this conference, more than 10,800 individuals from over 116 countries registered, of which 20% attended the first-ever hybrid UEG Week conference online.

Of the almost 3,000 submitted abstracts, 1,760 abstracts were presented and the scientific programme consisted of more than 200 live-streamed sessions. We have managed to make a selection of the finest presentations in this peer-reviewed conference report. Our primarily focus was new data and insights in the field of IBD but we also included presentations on colorectal carcinoma, hepatology, pancreatitis and pancreas cancer, as well as upper GI disorders including neoplasia in Barrett’s oesophagus and eosinophilic oesophagitis. In the case you would like to ‘ingest more science’, please note that almost 700 presentations were recorded, of which many can still be accessed via the UEG library.

I would like to end by citing Helena Cortez-Pinto, current EUG president, who commented during the 30 years of UEG anniversary session: ‘We should be incredibly proud of what we, as a community, have achieved’. We should be, keep up the good work and let’s meet again next year in Copenhagen!

Sincerely,

Marjolijn Duijvestein

 

Biography

Marjolijn Duijvestein works as a gastroenterologist in the IBD team of the Radboudumc in Nijmegen, the Netherlands. In 2012 she obtained her PhD at Leiden University and was trained as a gastroenterologist specialised in IBD disease at the Amsterdam UMC in Amsterdam. As part of her training, she gained experience at the University of California San Diego (UCSD, USA) and performed an internship at Alimentiv (former Robarts Clinical Trials), an academic research organisation dedicated to drug development for IBD. Her clinical activity and research are focused on IBD, in particular clinical and translational research.

Conflict of Interest Statement: Has served as an advisor for Echo pharma and Robarts Clinical Trials, reports nonfinancial support from Dr Falk Pharma, and received speaker fees from Janssen, Merck & Co., Pfizer, Takeda and Tillotts Pharma. Advisory boards Janssen, Takeda, BMS and Abbvie. 



Posted on 2 December, 2022